TECH Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 11.61% compared to Bio-Techne's net margin of 11.12%. Bio-Techne's return on equity of 7.4% beat Boston Scientific's return on equity of 8.91%.

Bio-Techne has a consensus price target of $81.38, signalling upside risk potential of 15.55%. On the other hand Boston Scientific has an analysts' consensus of $99.42 which suggests that it could grow by 9.62%. Given that Bio-Techne has higher upside potential than Boston Scientific, analysts believe Bio-Techne is more attractive than Boston Scientific.

Bio-Techne has a beta of 1.270, which suggesting that the stock is 27.034% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.800, suggesting its less volatile than the S&P 500 by 20.007%.

Bio-Techne has a quarterly dividend of $0.08 per share corresponding to a yield of 0.43%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Techne pays 29.99% of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne quarterly revenues are $289.5M, which are smaller than Boston Scientific quarterly revenues of $4.2B. Bio-Techne's net income of $33.6M is lower than Boston Scientific's net income of $468M. Notably, Bio-Techne's price-to-earnings ratio is 78.50x while Boston Scientific's PE ratio is 74.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne is 10.11x versus 8.45x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Haemonetics has a net margin of 11.61% compared to Bio-Techne's net margin of 9.79%. Bio-Techne's return on equity of 7.4% beat Haemonetics's return on equity of 13.51%.

Bio-Techne has a consensus price target of $81.38, signalling upside risk potential of 15.55%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 38.41%. Given that Haemonetics has higher upside potential than Bio-Techne, analysts believe Haemonetics is more attractive than Bio-Techne.

Bio-Techne has a beta of 1.270, which suggesting that the stock is 27.034% more volatile than S&P 500. In comparison Haemonetics has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.02%.

Bio-Techne has a quarterly dividend of $0.08 per share corresponding to a yield of 0.43%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Techne pays 29.99% of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend. Bio-Techne's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne quarterly revenues are $289.5M, which are smaller than Haemonetics quarterly revenues of $345.5M. Bio-Techne's net income of $33.6M is lower than Haemonetics's net income of $33.8M. Notably, Bio-Techne's price-to-earnings ratio is 78.50x while Haemonetics's PE ratio is 33.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne is 10.11x versus 3.02x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 11.61% compared to Bio-Techne's net margin of 25.43%. Bio-Techne's return on equity of 7.4% beat ResMed's return on equity of 23.76%.

Bio-Techne has a consensus price target of $81.38, signalling upside risk potential of 15.55%. On the other hand ResMed has an analysts' consensus of -- which suggests that it could grow by 10.65%. Given that Bio-Techne has higher upside potential than ResMed, analysts believe Bio-Techne is more attractive than ResMed.

Bio-Techne has a beta of 1.270, which suggesting that the stock is 27.034% more volatile than S&P 500. In comparison ResMed has a beta of 0.698, suggesting its less volatile than the S&P 500 by 30.155%.

Bio-Techne has a quarterly dividend of $0.08 per share corresponding to a yield of 0.43%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. Bio-Techne pays 29.99% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne quarterly revenues are $289.5M, which are smaller than ResMed quarterly revenues of $1.2B. Bio-Techne's net income of $33.6M is lower than ResMed's net income of $311.4M. Notably, Bio-Techne's price-to-earnings ratio is 78.50x while ResMed's PE ratio is 30.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne is 10.11x versus 7.11x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings has a net margin of 11.61% compared to Bio-Techne's net margin of 13.66%. Bio-Techne's return on equity of 7.4% beat Zimmer Biomet Holdings's return on equity of 8.63%.

Bio-Techne has a consensus price target of $81.38, signalling upside risk potential of 15.55%. On the other hand Zimmer Biomet Holdings has an analysts' consensus of $123.88 which suggests that it could grow by 18.58%. Given that Zimmer Biomet Holdings has higher upside potential than Bio-Techne, analysts believe Zimmer Biomet Holdings is more attractive than Bio-Techne.

Bio-Techne has a beta of 1.270, which suggesting that the stock is 27.034% more volatile than S&P 500. In comparison Zimmer Biomet Holdings has a beta of 1.019, suggesting its more volatile than the S&P 500 by 1.939%.

Bio-Techne has a quarterly dividend of $0.08 per share corresponding to a yield of 0.43%. Zimmer Biomet Holdings offers a yield of 0.92% to investors and pays a quarterly dividend of $0.24 per share. Bio-Techne pays 29.99% of its earnings as a dividend. Zimmer Biomet Holdings pays out 19.62% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne quarterly revenues are $289.5M, which are smaller than Zimmer Biomet Holdings quarterly revenues of $1.8B. Bio-Techne's net income of $33.6M is lower than Zimmer Biomet Holdings's net income of $249.1M. Notably, Bio-Techne's price-to-earnings ratio is 78.50x while Zimmer Biomet Holdings's PE ratio is 19.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne is 10.11x versus 2.83x for Zimmer Biomet Holdings. Usually stocks with elevated PS ratios are considered overvalued.